Przemyslaw W. Twardowski, M.D., medical oncologist and professor of medical oncology and urologic oncology at the Saint John’s Cancer Institute and his colleagues: Johann de Bono, M.B., Ch.B., Ph.D., Joaquin Mateo, M.D., Ph.D., Karim Fizazi, M.D., Ph.D., Fred Saad, M.D., Neal Shore, M.D., Shahneen Sandhu, M.D., Kim N. Chi, M.D., Oliver Sartor, M.D., Neeraj Agarwal, M.D., David Olmos, M.D., Ph.D., Antoine Thiery-Vuillemin, M.D., Ph.D., et al, have published a new study in the New England Journal of Medicine, entitled: Olaparib for Metastatic Castration-Rsistant Prostate Cancer. This publication demonstrates the significant benefit of therapy with olaparib (PARP inhibitor) in patients with advanced prostate cancer who harbor certain mutations of DNA repair system and who failed standard treatments.
FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer
Based on the results of that study, on May 19, 2020 the Food and Drug Administration (FDA) granted approval of olaparib, for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.
Resulting with a valuable treatment option for about 25% of patients with advanced prostate cancer with certain mutations of DNA repair. These mutations can be detected by performing an analysis of a patient’s cancer specimen and sometimes also on a specialized blood test.